Oncology & Cancer
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC
The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor ...
Sep 10, 2024
0
0